Water-Free Veterinary Injectable Co-Solution for Drug Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing veterinary injectable formulations of buparvaquone and imidocarb dipropionate are unstable and precipitate when water is added, leading to reduced therapeutic efficacy and increased toxicity, particularly at the injection site.
Innovation Solution
A veterinary injectable formulation comprising buparvaquone and imidocarb dipropionate stabilized with propyl glycol and N-methyl pyrrolidone, without water, forming a co-solution with fractionated coconut oil to maintain solubility and stability, ensuring both active ingredients are bioavailable.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Volume of stationary object
If water is added to the formulation, then the volume of the formulation increases, but the drug precipitates out of solution and therapeutic efficacy is reduced
Solution Approach 1:
The patent changes the solvent system from water-based to organic solvent-based (using N-methyl pyrrolidone and propyl glycol), fundamentally altering the dissolution parameters to prevent drug precipitation while maintaining appropriate formulation volume
Solution Approach 2:
The patent introduces N-methyl pyrrolidone and propyl glycol as intermediary substances that act as solvents to dissolve the drugs without causing precipitation, mediating between the drug molecules and the formulation matrix
2Volume of stationary object
If water is added to the formulation, then the formulation volume increases, but toxicity and irritation at the injection site increase
Solution Approach 1:
The patent changes the chemical composition parameters by replacing water with organic solvents (N-methyl pyrrolidone and propyl glycol), which fundamentally alters the toxicological profile and reduces local irritation at the injection site
Solution Approach 2:
The patent uses propyl glycol as a stabilizing agent that provides temporary protective effects during injection, reducing irritation and toxicity without requiring long-term presence in the formulation
3Stability of the object's composition
If imidocarb dipropionate is used in low concentrations, then the formulation is more stable, but the drug degrades over time
Solution Approach 1:
The patent introduces propyl glycol as an intermediary stabilizing agent that protects imidocarb dipropionate from degradation, mediating between the drug and environmental factors that cause degradation
Solution Approach 2:
The patent creates a composite solvent system combining N-methyl pyrrolidone and propyl glycol, where the synergistic interaction between the two substances provides enhanced stability for imidocarb dipropionate at low concentrations
4Productivity
If a single injectable formulation contains multiple active ingredients, then the number of injections is reduced, but the formulation complexity increases
Solution Approach 1:
The patent merges buparvaquone and imidocarb dipropionate into a single injectable formulation, combining multiple therapeutic activities in one product to reduce the number of injections required
Solution Approach 2:
The patent creates a universal formulation that can treat multiple parasitic infections (Theileria, Anaplasma, Babesia, Ehrlichia) simultaneously, making the single injection multi-functional and applicable to various disease states
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves prolonged therapeutic effects with reduced toxicity and irritation, effectively treating multiple parasitic infections in animals without the need for differential diagnosis, while minimizing side effects and reducing the number of injections required.
Implementation Method 1
A veterinary injectable formulation comprising buparvaquone and imidocarb dipropionate stabilized with propyl glycol and N-methyl pyrrolidone, without water, forming a co-solution with fractionated coconut oil to maintain solubility and stability
Data Source
AI summary
A veterinary single injectable formulation comprises buparvaquone, imidocarb or salts thereof and is substantially free from water. The formulation may comprise a stabilising agent which in one case is propyl glycol. The formulation is used in the treatment or prophylaxis of Theileria parasites and/or Anaplasma, Babesia and/or Ehrlichia parasites. The formulation may be administered in an amount of about 1ml per 20kg bodyweight in cattle, sheep, goats, and horses, or about 1ml per 15kg bodyweight in dogs.